Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Come on! You don't need an excuse for gettin out of "It'll be when it'll be".
Something like this is best case scenario for L, IMO. Read all the comments.
>>Prof John Gallacher, Director of Dementia Research UK and University of Oxford.
“Whatever your view on the decision taken by MHRA and NICE, the key take-away is that Lecanemab has been licensed. This is encouraging for the development of next-generation therapies that will provide greater benefit at less risk. There are grounds for optimism that these next-generation drugs will become available on the NHS. It is crucial, therefore, that the UK remains laser-focussed on developing these treatments.”
https://www.sciencemediacentre.org/expert-reaction-to-mhra-and-nice-news-on-lecanemab-for-alzheimers-disease-mhra-saying-lecanemab-licensed-for-adult-patients-in-the-early-stages-of-alzheimers-disease/
It's just the opposite actually. I see no signs of cryo activity in GBM. Besides, that'd make a lot of people privy to material information so I don't think so.
>>Just think of all of those frozen tumors waiting for processing.
No. They're supposed to work hand in hand. Do you really think MHRA or NICE want the appearance of not playing well together? It's political suicide. Sure there are a few rare moments where NICE breaks from MHRA but they pay the price politically speaking. So for LP to admit she hasn't even gotten the ball rolling after submitting to MHRA is very unusual, IMO.
Who's that make Mama Cass? LOL
I'm not trying to get anyone to forget anything but you are good at dodging my questions. The trial was never really meant for rGBM. Regardless, it's likely it had control pseudo progression patients crossing over (Meaning the chemo-rad was working but they crossed over anyway). Then there's the younger patients within that group with greater survival expectancy.
You do know that AI has no understanding of what it spits out, right?
Wouldn't that then mean they really weren't progressing but were still going over to the L arm?
>>PFS failed (due to pseudo-progression confoundment)
There it is again! LOL
"websites and other items that don’t matter."
Last time the disciples tried to make the argument that websites don't matter. LOL
But you have to admit, it's all very strange. If it's really all a scam wouldn't they dress up their website for poor green retail? I can only attribute it to two possibilities:
1. They're worried about promoting their own trial because they been told not to by someone. Only SEC essentials like PR's.
2. They have no interest in promoting NWBO over their own CDMO.
Any other possibilities I'm missing?
Performed my quarterly check. Sky's shinny new company still has all the same ancient information on their homepage where every investor goes for their first look.
>>The Company’s lead product, DCVax-L, is currently in a 348-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. The Company’s second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers. The Company has also conducted a Phase I/II trial with DCVax for late stage ovarian cancer together with the University of Pennsylvania. The Company previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.
Well, I guess nobody here wants to speculate (because disciples are so responsible and don't speculate) as to why LP didn't transfer the Direct tech when Cognate was sold??
LOL. Yeah, okay, tell that to suburban moms across America.
Everything you're describing is about yourself.
That'd be a longer process vs. heading to your local drug store. Could probably do both.
If you had GBM right now would you try it?
It's much more than that and you know it. It's also pays millions for services to the CEO CFO owned CDMO's while NWBO shareholders never seem to see any revenues. I've never come across anything like it in all my biotech investing. Anyone else?
>>this is what is called a development stage biotech.
As I was saying...
“As the drug has already been approved, it doesn’t have to undergo a complex approval procedure and could soon supplement the standard therapy for this deadly brain tumour.”
https://www.the-sun.com/health/12500081/antidepressant-vortioxetine-shrinks-glioblastoma-brain-tumours/amp/
I know but it gives them a better picture if they pretend to own 1000 shares just prior to the reverse splits.
>>Just pull up a stock chart....it accounts for splits.
$1480 to $0.30
A winner?!!! LOL. So delusional.
You're no investor that's for sure.
Disciples have been avoiding that question for a week! Think about that, LP has the tech knowhow stored with her private companies. Incredible.
Exactly. I guess they did. Like an afterthought.
>>I guess they forgot Direct
Do the math and tell us what anyone who bought in pre rs in 2007 holds today, then tell us anyone who bought pre rs in 2012 wha they hold today.
Same management, same product, same trial, same story.
>>NWBO (NWBO) has 2 splits in our NWBO split history database. The first split for NWBO took place on June 28, 2007. This was a 1 for 15 reverse split, meaning for each 15 shares of NWBO owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 66.6666666666667 share position following the split. NWBO's second split took place on September 26, 2012. This was a 1 for 16 reverse split, meaning for each 16 shares of NWBO owned pre-split, the shareholder now owned 1 share. For example, a 66.6666666666667 share position pre-split, became a 4.16666666666667 share position following the split.
Yes, shouldn't that be NWBO? Again, why did Cognate hold tech knowhow even after it was sold?
>>Because you need to have one company control the knowledge and the procedures for submission.
This seems to always be the lame reply when disciples get caught in a lie.
Wrong wrong wrong! Anyone who bought before the second reverse split is done.
>>As you know, nobody has “lost a dime” unless they chose to sell at a low that was less than their entry point.
Lots of words but totally dodged my question. Why does Cognate hold the Direct tech knowhow and not NWBO, and why even after they were taken over?
One of you "Science guys" please tell me how they get a 5% five year SOC figure based on those numbers?
How many of you "Science guys" have we seen come and go from here? Probably hundreds. So many predictions reach their expiration dates then become invalidated.
What ever happened to AE Kusterer, is this you now?
Absolutely not. LOL
>>I don’t think that you are a credible and authoritative source on the topic of emerging breakthroughs in cell-based immunotherapy.
Oh, and he didn't know the FDA would be out of the picture.
Back in 2015 he didn't know 5 year survival would drop from projected 25% to 13% as SOC has increased to at least 7-1/2%. He didn't know Cognate would go out the window. He didn't know Direct would be shelved. He didn't know other L trials would never get off the ground. He didn't know the CEO CFO would try for another private CDMO. He didn't know they'd never staff up. He didn't know they'd stay with the going concern warning year after year. He didn't know nine years later that there'd still be no clear evidence of patients surviving beyond SOC.
Not true. If I see a positive article relating to DCVAX that the disciple army hasn't already posted, I'll post it here. But that has nothing to do with why so many oncologist and medical journalist seem to know nothing about it or are ignoring the results.
It's been used for years and cheap as hell. If it works in a small trial it'll go straight to off label.
Not the point of my post, but you know that. It's why I always provide excerpts.
Yet another article straight out of the UK. You can all ignore it but, sorry, something is very wrong.
>>Experts say, should it prove effective, vortioxetine will be the first medicine in recent decades to improve the treatment of glioblastoma.
Commenting on the findings, Dr Simon Newman, chief scientific officer at The Brain Tumour Charity, who was not involved in the study, said: 'Any scientific developments that bring us closer to new treatments for glioblastoma are promising, as treatments haven’t changed in decades.
https://www.dailymail.co.uk/health/article-13872579/amp/Antidepressant-brain-cancer-tumour-glioblastoma-vortioxetine.html
>>Glioblastoma — 22 percent (ages 20–44), 9 percent (ages 45–54), 6 percent (ages 55–64)
https://ukhealthcare.uky.edu/markey-cancer-center/cancer-types/brain-cancer
Good luck to him. What's the schedule now, chemo-rad while they work on the vaccine, then administered when?